Plain-English translation of NCT06609226 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Sickle Cell Disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a long-term study of etavopivat, a new medication being tested to treat sickle cell disease and thalassemia — inherited blood disorders that affect how oxygen is carried through your body. If you have already been taking this medication in another study and it has helped you, this trial will continue that treatment and closely monitor how safe and effective it remains over many months or years.
While earlier studies showed that this medication can help people with these blood disorders, doctors need to understand how well and how safely it works when people take it for much longer periods — and whether the benefits continue over time.
You likely qualify if…
You likely don't qualify if…
You will continue taking the medication by mouth, in the same dose or formulation you were taking in the previous study. You will have regular visits with your study doctor — typically every few weeks or months — for blood tests, check-ins about how you're feeling, and monitoring for any side effects. The study may last up to about 5 years, though it could end sooner if the medication is approved for use in your country. Throughout, your doctor will be watching closely to make sure the treatment continues to work well and remains safe for you.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States